AbbVievs.Johnson & Johnson
ABBV vs JNJ · both in Big pharma, part of the Medicine, pharma & life science value chain: Large, diversified pharmaceutical groups with broad portfolios across therapeutic areas.
Johnson & Johnson is about 1.4× larger than AbbVie by market cap; Johnson & Johnson trades at the lower P/E (29.5 vs 120.6); year to date, Johnson & Johnson leads (+24.2% vs +8.6%).
Side by side
| ABBV | JNJ | |
|---|---|---|
| Market cap | $438B | $620B |
| Price | $248.08 | $256.98 |
| Today | −0.7% | −0.8% |
| Return YTD | +8.6% | +24.2% |
| Return 1Y | +27.2% | +63.0% |
| P/E | 120.6 | 29.5 |
| P/S | 7.0 | 6.4 |
| P/B | 308.7 | 7.6 |
Data as of 2026-07-11 · updates daily after U.S. close
The two companies
AbbVieABBV
Large biopharma with immunology (Skyrizi, Rinvoq), oncology and neuroscience.
Full ABBV profile →Johnson & JohnsonJNJ
American healthcare group with a large pharmaceutical division (Innovative Medicine) and medtech division (MedTech).
Full JNJ profile →More comparisons in Big pharma
See where ABBV and JNJ sit in the full Medicine, pharma & life science map — every segment from suppliers to end markets.Open the Life science value chain →